Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced the pricing of its previously announced underwritten public offering of 8,000,000 shares of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE